Microaxial Flow Pump Fails to Improve Outcomes in High-Risk PCI

Reevaluating Mechanical Support in High-Risk Coronary Revascularization

Managing patients with multivessel coronary artery disease and severely reduced ejection fraction remains a significant challenge for the heart team, as these individuals face high rates of periprocedural complications and long-term mortality [1, 2]. While coronary artery bypass grafting has historically been the preferred strategy for complex anatomy, percutaneous coronary intervention is increasingly utilized in patients deemed high-risk for surgery [2]. To mitigate the hemodynamic instability associated with complex stenting, clinicians often employ mechanical circulatory support to provide left ventricular unloading (a technique intended to maintain end-organ perfusion and reduce myocardial work during prolonged balloon inflations). However, the evidence supporting routine mechanical assistance in stable but high-risk settings has been less robust than the data guiding antiplatelet therapy or lipid management [3, 4]. Given the risks of vascular injury and bleeding associated with large-bore access, the necessity of prophylactic support remains a subject of intense clinical debate [5]. A new randomized controlled trial now provides definitive data on whether elective microaxial flow pump support improves long-term outcomes in this high-stakes population, offering critical guidance for interventional cardiologists weighing the risks and benefits of prophylactic mechanical assistance.

Trial Design and Patient Characteristics

The CHIP-BCIS3 trial (ClinicalTrials.gov number NCT05003817) was designed to address the clinical uncertainty surrounding mechanical support during high-risk revascularization. Funded by the U.K. National Institute for Health and Care Research, the study focused on a high-risk cohort where complex percutaneous coronary intervention (PCI) is often complicated by severely impaired left ventricular function. This combination carries a high risk of death and periprocedural complications. To evaluate the efficacy of routine support, the researchers randomly assigned 300 patients with severe left ventricular dysfunction and extensive coronary artery disease in a 1:1 ratio to either elective mechanical unloading or standard care.

Of the total enrollment, 148 patients were assigned to receive a microaxial flow pump (a catheter-based device inserted into the left ventricle to actively move blood into the aorta and reduce myocardial work). The remaining 152 patients were assigned to the standard care group, which involved planned complex PCI without elective mechanical assistance. This comparison aimed to determine if elective left ventricular unloading could improve long-term clinical outcomes compared to conventional procedural management in patients with significantly reduced cardiac reserve. For practicing cardiologists, these baseline characteristics represent the exact phenotype of patients who frequently trigger heart team debates regarding the necessity of prophylactic hemodynamic support.

Primary Composite Endpoint and Win Ratio Analysis

The researchers evaluated the efficacy of elective mechanical support using a hierarchical composite primary outcome (a structured endpoint designed to capture the most relevant clinical complications following high-risk revascularization). This composite included death from any cause, disabling stroke, spontaneous myocardial infarction, hospitalization for cardiovascular causes, or periprocedural myocardial injury. By incorporating both catastrophic events and procedural complications, the study aimed to provide a comprehensive assessment of whether mechanical unloading offers a protective benefit that outweighs its inherent procedural risks. This primary outcome was assessed at a minimum of 12 months post-procedure, ensuring that the analysis accounted for both immediate periprocedural safety and longer-term clinical stability.

To analyze these multi-component outcomes, the authors utilized a win ratio (a statistical method that prioritizes the most clinically significant events in pairwise comparisons). In this model, every patient in the microaxial flow pump group is compared to every patient in the standard care group, starting with the most severe outcome, such as death, and moving down the hierarchy to less severe events like periprocedural injury. This approach prevents less frequent but more severe events from being overshadowed by more common, less critical ones. The study achieved a median follow-up duration of 22 months, with an interquartile range of 16 to 30 months, providing a robust longitudinal window to observe the potential impact of left ventricular unloading on patient prognosis.

Clinical Efficacy and Mortality Trends

The primary analysis revealed that routine mechanical support failed to improve overall clinical outcomes. When ranking clinical events by severity to determine which patient in a pair fared better, 36.6% of pairwise comparisons favored the microaxial flow pump, while 43.0% of pairwise comparisons favored standard care. This resulted in a win ratio of 0.85 (95% confidence interval [CI], 0.63 to 1.15). The difference in pairwise comparisons between groups was -6.4 percentage points, indicating that the mechanical support strategy did not provide a statistical advantage over standard procedural care. With a P value of 0.30 for the primary outcome comparison, the researchers found no evidence that elective unloading significantly altered the composite clinical trajectory for these high-risk patients.

Mortality data from the study further underscored the lack of benefit associated with routine microaxial flow pump use in this population. Death from any cause occurred in 47 patients in the microaxial-flow-pump group, compared to 33 patients in the standard-care group. This distribution yielded a hazard ratio for death from any cause of 1.54 (95% CI, 0.99 to 2.41). Although the study was not primarily powered to detect differences in individual components like mortality, these trends suggest that the addition of mechanical support does not mitigate the inherent risks of complex revascularization in patients with severe left ventricular dysfunction. Ultimately, the trial demonstrated that elective left ventricular unloading with a microaxial flow pump did not reduce the risk of major adverse clinical outcomes at a minimum of 12 months. For the practicing clinician, these findings suggest that routine prophylactic use of these devices in this specific patient population may not be justified based on long-term efficacy alone.

Safety and Procedural Complications

Beyond the primary efficacy outcomes, the trial evaluated the safety profile of routine mechanical support in the context of high-risk percutaneous coronary intervention. A critical concern with the use of large-bore access required for a microaxial flow pump is the potential for increased procedural morbidity, particularly regarding access-site integrity and systemic coagulation. However, the researchers found that the addition of the device did not significantly worsen the safety profile of the procedure compared to standard care. Specifically, there was no material between-group difference in the risk of bleeding or vascular complications among the 300 patients enrolled in the study.

The lack of a significant increase in these adverse events is notable given the complexity of the cases and the baseline frailty of the patient population, all of whom had severely impaired left ventricular function. While the microaxial flow pump group did not demonstrate a reduction in major adverse clinical outcomes, the data indicate that the strategy was not associated with a disproportionate rise in immediate procedural harm. Clinicians managing these high-risk cases can conclude that while elective unloading did not improve the 12-month clinical trajectory, it also did not introduce a statistically significant excess of bleeding or vascular injury compared to the standard interventional approach. This safety data provides some reassurance for operators who choose to deploy mechanical support on a case-by-case basis for hemodynamic rescue, even if routine prophylactic use is not supported by the efficacy endpoints.

References

1. Group TB2S. A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. New England Journal of Medicine. 2009. doi:10.1056/nejmoa0805796

2. Serruys PW, Morice M, Kappetein AP, et al. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. New England Journal of Medicine. 2009. doi:10.1056/nejmoa0804626

3. Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002. doi:10.1136/bmj.324.7329.71

4. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal. 2019. doi:10.1093/eurheartj/ehz455

5. Brieger DG, Rao K, Nagaraja V, Bhindi R, Allahwala U. The use of glycoprotein IIb/IIIa inhibitors in elective PCI - A systematic review and meta-analysis of randomised trials.. Vascular pharmacology. 2025. doi:10.1016/j.vph.2025.107500